Every material Form 8-K Moleculin Biotech, Inc. has filed with the SEC since October 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Moleculin Biotech announced that an abstract on interim results from its pivotal MB-108 Phase 2/3 trial of Annamycin has been accepted for poster presentation at the 2026 American Society of Hematology Annual Meeting, held December 12-15, 2026 in New Orleans. The data cover the first 45 randomized patients, so the results are early and preliminary, and the independent Data Monitoring Committee recommended the study continue without amendment.
Complete remission rates were 43% and 36% in the two Annamycin arms, versus 12% in the placebo arm, among the first 45 randomized patients.
No signs of cardiotoxicity were observed through the data cutoff; cardiac safety data will be reviewed at the second interim analysis.
The second interim analysis is expected in early 2027.
The poster presentation is scheduled at the ASH meeting, December 12-15, 2026.
Moleculin Biotech announced that dosing is complete in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia. The company says it remains on track to report comprehensive Part A data in the first quarter of 2027, with the full 90-patient population used to select the Annamycin dose for Part B.
Dosing completed in Part A of the MIRACLE trial, which the company describes as a randomized, double-blind study with a 90-patient Part A population.
Comprehensive Part A data readout remains expected in the first quarter of 2027.
Final Part A population is expected to be about 50/50 between 7+3 chemotherapy and venetoclax-based regimen patients, versus about 70/30 among the first 45 subjects.
The filing states the company will require significant additional financing, for which it has no commitments.
Moleculin Biotech's 1-for-20 reverse stock split takes effect at 12:01 a.m. Eastern Time on October 20, 2026, and the stock will keep the MBRX ticker under a new CUSIP. Shares outstanding will fall from approximately 20.91 million to approximately 1.05 million, and proportional adjustments will apply to outstanding options, RSUs, warrants and the equity plan reserve, while authorized shares stay at 500 million.
Effective 12:01 a.m. ET on October 20, 2026; trading on The Nasdaq Capital Market under MBRX with new CUSIP 60855D507
Shares outstanding reduced from approximately 20.91 million to approximately 1.05 million; authorized shares remain at 500 million
Stockholders approved a split ratio range of 1-for-2 to 1-for-20 at the annual meeting completed October 9, 2026; the board selected 1-for-20
Fractional shares will be paid in cash based on the average closing price over the five trading days before the split
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Moleculin Biotech, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →